157 related articles for article (PubMed ID: 12960517)
1. Immunotherapy of lymphoma: update and review of the literature.
Berdeja JG
Curr Opin Oncol; 2003 Sep; 15(5):363-70. PubMed ID: 12960517
[TBL] [Abstract][Full Text] [Related]
2. Current standards and future strategies in immunochemotherapy of non-Hodgkin's lymphoma.
Motta G; Cea M; Carbone F; Augusti V; Moran E; Patrone F; Nencioni A
J BUON; 2011; 16(1):9-15. PubMed ID: 21674844
[TBL] [Abstract][Full Text] [Related]
3. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
[TBL] [Abstract][Full Text] [Related]
4. [Innovative antibody-therapies for malignant lymphomas].
Müller AM; Rawluk J; Thierry V; Brink I; Engelhardt M
Dtsch Med Wochenschr; 2005 Dec; 130(48):2783-8. PubMed ID: 16307409
[TBL] [Abstract][Full Text] [Related]
5. Follicular lymphoma: today's treatments and tomorrow's targets.
Aurora V; Winter JN
Expert Opin Pharmacother; 2006 Jul; 7(10):1273-90. PubMed ID: 16805715
[TBL] [Abstract][Full Text] [Related]
6. Emerging immunotherapy in pediatric lymphoma.
Erker C; Harker-Murray P; Burke MJ
Future Oncol; 2016 Jan; 12(2):257-70. PubMed ID: 26616565
[TBL] [Abstract][Full Text] [Related]
7. An Update on the Use of Immunotherapy in the Treatment of Lymphoma.
Marron TU; Kalac M; Brody J
Curr Hematol Malig Rep; 2017 Aug; 12(4):282-289. PubMed ID: 28735365
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines.
Maloney DG
J Clin Oncol; 2005 Sep; 23(26):6421-8. PubMed ID: 16155029
[TBL] [Abstract][Full Text] [Related]
9. [Advancement of biotherapy for malignant lymphoma].
Jiang WQ
Ai Zheng; 2005 Aug; 24(8):1027-32. PubMed ID: 16086888
[TBL] [Abstract][Full Text] [Related]
10. Antibody therapy of lymphoma.
Illidge TM; Bayne MC
Expert Opin Pharmacother; 2001 Jun; 2(6):953-61. PubMed ID: 11585011
[TBL] [Abstract][Full Text] [Related]
11. Non-myeloablative radioimmunotherapy for non-Hodgkin's lymphoma.
Schaefer-Cutillo J; Friedberg JW
Semin Hematol; 2008 Apr; 45(2):110-7. PubMed ID: 18381106
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review.
Geynisman DM; Chien CR; Smieliauskas F; Shen C; Shih YC
Hum Vaccin Immunother; 2014; 10(11):3415-24. PubMed ID: 25483656
[TBL] [Abstract][Full Text] [Related]
13. Novel approaches in cancer immunotherapy -- a light at the end of the tunnel.
Joshi M; Pal SK; Drabick JJ
Discov Med; 2016 Jun; 21(118):479-87. PubMed ID: 27448784
[TBL] [Abstract][Full Text] [Related]
14. Active and passive immunotherapy for lymphoma: proving principles and improving results.
Brody J; Kohrt H; Marabelle A; Levy R
J Clin Oncol; 2011 May; 29(14):1864-75. PubMed ID: 21482977
[TBL] [Abstract][Full Text] [Related]
15. What is new in lymphoma?
Cheson BD
CA Cancer J Clin; 2004; 54(5):260-72. PubMed ID: 15371284
[TBL] [Abstract][Full Text] [Related]
16. A review of monoclonal antibody therapies in lymphoma.
Teo EC; Chew Y; Phipps C
Crit Rev Oncol Hematol; 2016 Jan; 97():72-84. PubMed ID: 26318093
[TBL] [Abstract][Full Text] [Related]
17. [Monoclonal antibody treatment of malignant lymphoma].
Buske C; Dreyling M; Unterhalt M; Hiddemann W
Internist (Berl); 2004 Dec; 45(12):1370-7. PubMed ID: 15517123
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
19. Changing therapeutic landscape--the last decade.
Aurer I
Transfus Apher Sci; 2011 Apr; 44(2):155-9. PubMed ID: 21320799
[TBL] [Abstract][Full Text] [Related]
20. Vaccines versus immunotherapy: overview of approaches in deciding between options.
Dalgleish AG
Hum Vaccin Immunother; 2014; 10(11):3369-74. PubMed ID: 25625932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
